Post-listing reviews
Through the Prescribed List reforms, we formalised post-listing reviews to safeguard the settings of the Prescribed List.
On 12 May 2022, the Prostheses List Advisory Committee (now the Medical Devices and Human Tissue Advisory Committee) supported pilot post-listing reviews for 4 groups of devices:
- metal-backed patellae
- surgical guides and biomodels
- spinal cord stimulators
- urogynaecological mesh (mid-urethral sling) devices.
We used the learnings from these reviews to inform the finalisation of our post-listing review framework.
Active reviews
- Spinal cord stimulators
Learn about our review into spinal cord stimulators. - Surgical guides and biomodels
Learn about our review into surgical guides and biomodels – stage 2.
Completed reviews
- Metal-backed patellae
Learn about the outcome and implementation of the review into metal-backed patellae. - Urogynaecological mesh devices
Learn about the outcome and implementation of the review into urogynaecological mesh (mid-urethral sling) devices. - Surgical guides and biomodels
Learn about the outcome and implementation of the review into surgical guides and biomodels – stage 1.
Post-listing review framework
We prepared a post-listing review framework to promote a consistent approach for all post-listing reviews.
The framework outlines how we:
- identify devices that may be appropriate for a post-listing review
- prioritise devices identified as appropriate for a post-listing review
- determine the scope of a post-listing review
- undertake a post-listing review
- inform and consult with stakeholders and sponsors during the post-listing review
- action the outcomes and actions arising from a post-listing review.